PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2024Cancer Research0 citations

Abstract 2976: The potential use of butyrate and propionate to inhibit oncogenic phenotypes in oral squamous cell carcinoma and triple negative breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAngel J. Amaral Maisonet

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Angel J. Amaral Maisonet (2024) studied this question.

synapsesocial.com/papers/68e72ceab6db6435876a70f0https://doi.org/10.1158/1538-7445.am2024-2976
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 7070: Butyrate modulates key oncogenic pathways in oral squamous cell carcinoma: Insights from transcriptomic profiling.2026
  2. 2Abstract 3067: Short-chain fatty acids suppress invasion and clonogenic survival in triple-negative breast cancer cells2026
  3. 3Abstract 3063: Selective cytotoxicity of butyrate highlights its potential as a targeted anti-cancer agent2026
  4. 4Exploring the anti-cancer potential of gut microbiota-derived short-chain fatty acids in ovarian cancer: a comparative analysis of sodium butyrate and sodium propionate on proliferation, cell cycle, and apoptosis2026
  5. 5Abstract 3056: Inhibition of oncogenic phenotypes by hexanoate in triple-negative breast cancer2026